De Felice F et al. - The purpose of the current study was to determine the long-term outcomes of chemoradiotherapy (CRT) in patients with anal carcinoma.In the treatment of anal carcinoma, excellent anal dysfunction-free survival (ADFS) and OS, and valid local failure-free survival (LFFS), locoregional failure-free survival (LRFFS), and distant metastasis-free survival (DMFS) were achieved with definitive CRT.

Methods

• The study was conducted based on a retrospective chart review of patients with anal carcinoma treated with CRT.

Results

• 65 patients were studied.
• The incidence of grade 3 or greater acute toxicity was 24.6%.
• The 5-year OS, LFFS, LRFFS, and DMFS were 75.3%, 60.2%, 74.2%, and 66.2%, respectively.
• Complete clinical response and tumor stage at the time of diagnosis were the best predictors of OS and local failure, respectively.